AstraZeneca PLC
Other OTCTotal Valuation
AstraZeneca PLC carries a market capitalization of 294.40B, placing it among publicly traded companies globally. Its enterprise value stands at 296.02B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 294.40B |
| Enterprise Value | 296.02B |
Share Statistics
AstraZeneca PLC currently has 1.55B shares outstanding.
| Shares Outstanding | 1.55B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
AstraZeneca PLC trades at a trailing price-to-earnings ratio of 26.61. The price-to-sales ratio is 4.63, and the price-to-book ratio stands at 23.95.
| PE Ratio | 26.61 |
| PS Ratio | 4.63 |
| PB Ratio | 23.95 |
| P/TBV Ratio | -26.24 |
| P/FCF Ratio | 13.38 |
| P/OCF Ratio | 18.67 |
Enterprise Valuation
On an enterprise value basis, AstraZeneca PLC trades at an EV/EBITDA multiple of 21.54 and an EV/FCF ratio of 13.52. The EV/Sales ratio of 5.04 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 21.54 provides insight into valuation relative to core operating earnings.
| EV / Sales | 5.04 |
| EV / EBITDA | 21.54 |
| EV / EBIT | 21.54 |
| EV / FCF | 13.52 |
Financial Position
AstraZeneca PLC maintains a current ratio of 0.94, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 60.80, indicating elevated leverage, while an interest coverage ratio of 8.06 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 0.94 |
| Quick Ratio | 0.19 |
| Debt / Equity | 60.80 |
| Debt / EBITDA | 2.16 |
| Interest Coverage | 8.06 |
Financial Efficiency
AstraZeneca PLC posts a return on equity of 137.17 and a return on invested capital of 14.94.
| Return on Equity (ROE) | 137.17 |
| Return on Assets (ROA) | 9.38 |
| Return on Invested Capital (ROIC) | 14.94 |
| Return on Capital Employed (ROCE) | 31.09 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.80 |
Taxes
Over the trailing twelve months, AstraZeneca PLC has paid 2.17B in income taxes, reflecting an effective tax rate of 17.49.
| Income Tax | 2.17B |
| Effective Tax Rate | 17.49 |
Stock Price Statistics
AstraZeneca PLC's stock has gained approximately 44.61959% over the past 52 weeks. The 50-day moving average sits at 183.86, while the 200-day moving average is 161.39.
| Beta (5Y) | N/A |
| 52-Week Price Change | 44.61959% |
| 50-Day Moving Average | 183.86 |
| 200-Day Moving Average | 161.39 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, AstraZeneca PLC generated 58.74B in revenue and converted that into 10.23B in net income, yielding earnings per share of 6.56. EBITDA reached 13.74B, while operating income came in at 13.74B.
| Revenue | 58.74B |
| Gross Profit | 48.11B |
| Operating Income | 13.74B |
| Pretax Income | 12.40B |
| Net Income | 10.23B |
| EBITDA | 13.74B |
| EBIT | 13.74B |
| Earnings Per Share (EPS) | 6.56 |
Balance Sheet
AstraZeneca PLC holds 5.74B in cash and equivalents against 29.62B in total debt, resulting in a net debt position of 22.11B. Total book value stands at 11.36B, with working capital of -1.89B providing operational flexibility.
| Cash & Cash Equivalents | 5.74B |
| Total Debt | 29.62B |
| Net Debt | 22.11B |
| Equity (Book Value) | 11.36B |
| Book Value Per Share | 7.33 |
| Working Capital | -1.89B |
Cash Flow
AstraZeneca PLC produced 14.58B in operating cash flow over the past twelve months. After subtracting -5.90B in capital expenditures, free cash flow totaled 8.67B - equivalent to 5.59 per share.
| Operating Cash Flow | 14.58B |
| Capital Expenditures | -5.90B |
| Free Cash Flow | 8.67B |
| FCF Per Share | 5.59 |
Margins
AstraZeneca PLC operates with a gross margin of 81.90, reflecting its pricing power and cost economics. The operating margin of 23.40 and net profit margin of 17.41 provide insight into operational efficiency.
| Gross Margin | 81.90 |
| Operating Margin | 23.40 |
| Pretax Margin | 21.11 |
| Profit Margin | 17.41 |
| EBITDA Margin | 23.40 |
Dividends & Yields
The company's payout ratio of 48.54 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 3.21 |
| Dividend Yield | N/A |
| Payout Ratio | 48.54 |
| Shareholder Yield | 2.77 |
| FCF Yield | 7.48 |
Scores
AstraZeneca PLC posts an Altman Z-Score of 4.63, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.63 |